Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Rises By 98.3%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totaling 574,897 shares, a growth of 98.3% from the June 30th total of 289,957 shares. Based on an average daily trading volume, of 30,260,865 shares, the days-to-cover ratio is presently 0.0 days. Currently, 16.9% of the company’s shares are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Catheter Precision stock. Millennium Management LLC purchased a new stake in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision as of its most recent SEC filing. Institutional investors own 20.34% of the company’s stock.

Catheter Precision Trading Down 5.3%

Shares of VTAK traded down $0.01 during trading hours on Friday, hitting $0.26. The company had a trading volume of 435,515 shares, compared to its average volume of 4,345,545. Catheter Precision has a 52-week low of $0.23 and a 52-week high of $4.31. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.35. The stock’s 50 day moving average price is $0.81 and its 200 day moving average price is $1.18. The firm has a market cap of $949,430.00, a P/E ratio of -0.02 and a beta of -1.07.

Catheter Precision (NYSEAMERICAN:VTAK) last issued its earnings results on Monday, May 18th. The company reported ($1.39) earnings per share for the quarter, beating the consensus estimate of ($20.90) by $19.51. The company had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $1.60 million. Catheter Precision had a negative return on equity of 76.51% and a negative net margin of 1,297.56%.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.